Theradiag Signs Partnership Agreement With Biogaran

Lisa Tracker monitoring tests offered with biosimilars from Biogaran

THERADIAG, a company specialized in in vitro diagnostics and theranostics, recently announces the signing of a partnership agreement with the pharmaceutical company Biogaran to supply its Lisa Tracker kits for Biogaran biosimilar monitoring.

As part of this agreement, Biogaran has referenced Lisa Tracker monitoring kits in France to support the supply of its biosimilars. Theradiag will be in charge of setting up, training in the use of kits by laboratories and follow-up of clinicians' requests for monitoring.

Biogaran, a French generic medicine laboratory, chose since its creation in 1996 to offer medicines that meet the expectations of patients, pharmacists and doctors alike and to promote their proper use. In 2014, he creates BIOGARAN biosimilar to launch in February 2015, the 1 st anti-TNF biosimilar in France, approved by the EMA (European Medicines Agency), the Remsima (infliximab). Biogaran is now one of the major players in complex biosimilars and the number two biosimilar drug in hospitals.

"It is a pleasure to associate Theradiag's know-how with our skills. " Says Daniel Roederer, Director of Operations Biogaran.

"This agreement with Biogaran allows us, together with our partnerships with Janssen, MSD, Pfizer and Biogen, to provide our Lisa Tracker kits with all the infliximab on the market but also for other monoclonal antibodies. This is also very good news for doctors and their patients who will be able to benefit from treatments with greater personalization. " Adds Michel Finance, CEO of Theradiag.

About Theradiag

With its expertise in the distribution, development and manufacture of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (alliance of treatment and diagnosis), which measure the effectiveness of biotherapies in the treatment of auto diseases. -immunes and cancer. Theradiag thus participates in the development of "personalized medicine", promoting the individualization of treatments, the measurement of their effectiveness and the prevention of drug resistance. Theradiag markets the LISA TRACKER range, CE marked, a complete multiparametric diagnostic solution for the management of patients with autoimmune diseases treated with biotherapies. The company is based in Marne-la-Vallée and has 65 employees.

For more information, visit www.theradiag.com.